The Effects of Empagliflozin on Renal Outcomes in Post Severe Acute Kidney Injury Survivors

Sponsor
Chulalongkorn University
Study ID
NCT05360615
Phase
PHASE1
Status
Active Not Recruiting

Conditions

  • Empagliflozin in Post AKI Stage 2-3

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Effects of Empagliflozin compared with placebo in post severe acute kidney injury survivors, evaluated by MAKE365.

Key Dates

Start date
Jul 1, 2022
Status verified
Aug 2025
Primary completion
Jun 1, 2024
Completion
Jul 1, 2026

Study Design

Enrollment
147 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Empagliflozin
  • Placebo Comparator: Placebo

Primary Outcome Measure

MAKE365 [ Time Frame: 1 year ]